title: Early development of endocrine and metabolic consequences after treatment of central nervous system tumors in children.
abstract: OBJECTIVE
  Survival after childhood cancer has dramatically improved during last few decades, implying the need for evaluation and correction of late consequences of the disease and its treatment. The aim of this study was to characterize endocrine and metabolic late effects after treatment of brain tumors in children.
  
  
  METHODS
  Late complications were analyzed in 51 children treated for brain tumors at the Hospital of Lithuanian University of Health Sciences during 2000-2011. Data on late endocrine and metabolic effects were collected from medical records. Most frequently patients suffered from low-grade glioma (n=17, 33.3%) and medulloblastoma (n=13, 25.5%). The majority (n=42, 82.4%) of the patients underwent surgery; 29 (56.9%) received radiotherapy (RT); 26 (51.0%), chemotherapy; and 17 (33.4%), combined treatment.
  
  
  RESULTS
  The median follow-up was 21 months (range 0.25-10.6 years). Most common endocrine consequence was low serum insulin-like growth factor (IGF-I) levels (58.3%), found on average in 30.7 months after cancer treatment. Short stature was observed in 34.6% (mean time to development, 47.7 months), and hypothyroidism in 40.7% of patients (mean time to development, 63.6 months). Low bone mineral density was found in 50.0% of the cases after 44.5 months and overweight in 30.0% after 49.9 months of follow-up.
  
  
  CONCLUSIONS
  Survivors of brain tumors suffer from numerous endocrine and metabolic consequences, majority of them developing within the first 5 years after brain tumor therapy. An active follow-up aiming for early diagnosis and therapy is essential for improvement of quality of life in these patients.
authors.affiliation: Department of Children Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. Electronic address: ramegle@gmail.com.
authors.forename: Eglė
authors.initials: E
authors.lastname: Ramanauskienė
authors.affiliation: Department of Children Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
authors.forename: Liutauras
authors.initials: L
authors.lastname: Labanauskas
authors.affiliation: Institute of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
authors.forename: Rasa
authors.initials: R
authors.lastname: Verkauskienė
authors.affiliation: Department of Children Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
authors.forename: Rima
authors.initials: R
authors.lastname: Sileikienė
mesh_terms: D001932:Brain Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy / Q000009:adverse effects; D004700:Endocrine System Diseases / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005910:Glioma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy; D006801:Humans; D006854:Hydrocortisone / Q000172:deficiency; D007037:Hypothyroidism / Q000453:epidemiology / Q000209:etiology; D015994:Incidence; D008297:Male; D008527:Medulloblastoma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy; D008659:Metabolic Diseases / Q000453:epidemiology* / Q000209:etiology; D009765:Obesity / Q000453:epidemiology / Q000209:etiology; D015995:Prevalence; D017526:Receptor, IGF Type 1 / Q000172:deficiency; D013961:Thyroid Gland / Q000503:physiopathology
chemical_list: D017526:Receptor, IGF Type 1; D006854:Hydrocortisone
keywords: Cancer survivors; Children brain tumors; Endocrinopathy; Late effects; Metabolic complications